AstraZeneca Pharma India Ltd. — AGM Information 2022

Aug 9, 2022

==> picture [475 x 82] intentionally omitted <==

August 8, 2022

The Manager- Listing BSE Limited Corporate Relationship Dept., 5[th] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai - 400001

National Stock Exchange of India Limited

Exchange plaza, 5[th] Floor, Plot No. C/1, G Block Bandra –Kurla Complex, Bandra (E), Mumbai - 400051

Dear Sir,

Sub: Summary of Proceedings of 43[rd] Annual General Meeting – Ref: Scrip code BSE: 506820, NSE: ASTRAZEN

Pursuant to the provisions of Regulation 30 read with Part A of Schedule III to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the following business were transacted at the 43[rd] Annual General Meeting (AGM) of the Company held on August 8, 2022 at 3.00 P.M. through Video Conferencing/Other Audio Visual Means:

1. Adoption of Financial Statements for the financial year ended March 31, 2022 and the Reports of the Board of Directors and Auditors thereon.

2. Confirmation of the payment of interim dividend of Re. 2/- per Equity Share for the financial year 2021-22 and declaration of final dividend of Re. 8/- per Equity Share.

3. Appointment of Mr. Rajesh Marwaha (DIN: 01458768), who retires by rotation, and being eligible, offers himself for re- appointment.

4. Appointment of Ms. Shilpa Shridhar Divekar as an Independent Director of the Company to hold office for a term of five consecutive years i.e. from December 29, 2021 to December 28, 2026, not liable to retire by rotation.

5. Consideration of material Related Party Transactions with AstraZeneca UK Limited for an amount not exceeding in aggregate Rs. 400 crore for the period from 43[rd] Annual General Meeting until the 44[th] Annual General Meeting.

==> picture [452 x 64] intentionally omitted <==

==> picture [475 x 82] intentionally omitted <==

1. Consideration of material Related Party Transactions with AstraZeneca AB, Sweden for an amount not exceeding in aggregate Rs. 120 crore for the period from 43[rd] Annual General Meeting until the 44[th] Annual General Meeting.

2. Ratification of Cost Auditor’s remuneration.

Kindly note that voting results will be announced upon the receipt of Scrutinizer’s Report and will be submitted as per Regulation 44(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take same on record.

For AstraZeneca Pharma India Limited

BHUVANAGI Digitally signed by BHUVANAGIRI RI RUDRA RUDRA PRATAP PRATAP Date: 2022.08.09 16:54:19 +05'30'

Pratap Rudra Company Secretary & Legal Counsel

==> picture [452 x 64] intentionally omitted <==